Hans Jeppsson
Directeur Financier/CFO chez VICORE PHARMA HOLDING AB
Fortune : 8 227 $ au 30/04/2024
Postes actifs de Hans Jeppsson
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| VICORE PHARMA HOLDING AB | Directeur Financier/CFO | 01/01/2017 | - |
| Public Communications Contact | 01/01/2017 | - | |
Vicore Pharma AB
 Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden. | Corporate Officer/Principal | - | - |
INIM Pharma AB
 INIM Pharma AB Pharmaceuticals: MajorHealth Technology INIM Pharma AB operates as drug development company that focuses on the development of immunomodulatory drugs for interstitial lung diseases. It develops a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis. The company was founded by Carl-Johan Dalsgaard and is headquartered in Stockholm, Sweden. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Hans Jeppsson
Anciens postes connus de Hans Jeppsson
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Danske Bank A/S (Sweden) | Analyst-Equity | - | - |
Formation de Hans Jeppsson
| University of Gothenburg | Doctorate Degree |
| Handelshögskolan i Göteborg | Doctorate Degree |
Statistiques
Internationale
| Suède | 7 |
Opérationnelle
| Doctorate Degree | 2 |
| Graduate Degree | 2 |
| Analyst-Equity | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
| Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VICORE PHARMA HOLDING AB | Health Technology |
| Entreprise privées | 3 |
|---|---|
| Danske Bank A/S (Sweden) | Finance |
Vicore Pharma AB
Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden. | Health Technology |
INIM Pharma AB
INIM Pharma AB Pharmaceuticals: MajorHealth Technology INIM Pharma AB operates as drug development company that focuses on the development of immunomodulatory drugs for interstitial lung diseases. It develops a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis. The company was founded by Carl-Johan Dalsgaard and is headquartered in Stockholm, Sweden. | Health Technology |
- Bourse
- Insiders
- Hans Jeppsson
- Expérience
